NCT00445328View on ClinicalTrials.gov

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Venous Thromboembolism
Interventions
DRUG

Dalteparin (Fragmin)

Dalteparin 5000 IU once daily subcutaneously for 6-14 days.

DRUG

Unfractionated heparin

Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.

Trial Locations (7)

452001

Pfizer Investigational Site, Indore

500 068

Pfizer Investigational Site, Hyderabad

380 054

Pfizer Investigational Site, Ahmedabad

680 005

Pfizer Investigational Site, Thrissur

600 006

Pfizer Investigational Site, Chennai

700 029

Pfizer Investigational Site, Kolkata

700 054

Pfizer Investigational Site, Kolkata

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY